Tempest Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Tempest Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TPST
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001544227
Board of directors
-
Christine A. Pellizzari · DirectorSince 2023
-
Geoffrey Nichol · DirectorSince 2023
-
Michael Raab · DirectorSince 2023
-
Ronit Simantov · DirectorSince 2023
-
Stephen R. Brady · Director · President and CEOSince 2023
-
Thomas W. Dubensky · Director · PresidentSince 2023
Chief executives
Stephen R. Brady
· Chief Executive Officer
Dates unknown
Board connections
2 of this board's directors also sit on 2 other boards.
- via Michael Raab
- via Christine A. Pellizzari
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2024 | Versant Venture Capital VI, L.P. 10% owner | Open-market sale | −387,999 | $1.10 | $426,799 |
| Aug 8, 2024 | Versant Venture Capital VI, L.P. 10% owner | Open-market sale | −400,000 | $1.35 | $540,000 |
| Jul 3, 2024 | Stephen R. Brady Director, Officer (President and CEO) | Open-market purchase | +35,000 | $2.11 | $73,850 |
| Jul 2, 2024 | Whiting Samuel Officer (Chief Medical Officer) | Open-market purchase | +4,672 | $2.13 | $9,951 |
| Jun 28, 2024 | Trojanowski Justin Officer (Corporate Controller) | Open-market purchase | +7,500 | $2.16 | $16,200 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.